1. A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
- Author
-
Yuki Haruta, Masanori Azuma, Toshikatsu Sado, Ryuichi Saito, Yoshimune Miyazaki, Akihiro Noda, Reina Kitagawa, Yasutaka Hori, Sayaka Fujimoto, Yoshinori Hasegawa, Tetsuya Ueda, and Ryosuke Yamamura
- Subjects
haemophilia ,factor V inhibitors ,hem‐irAE ,immune checkpoint inhibitors ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract A 73‐year‐old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was decreased, and FV inhibitors were observed. There was no history of PT or APTT prolongation or bleeding before the use of atezolizumab. Atezolizumab‐induced coagulation FV inhibitor was diagnosed. After 2 weeks, the PT and APTT spontaneously normalized. FV activity improved and the FV inhibitors disappeared after 6 and 9 weeks, respectively.
- Published
- 2024
- Full Text
- View/download PDF